中国麻风皮肤病杂志 ›› 2021, Vol. 37 ›› Issue (3): 157-159.doi: 10.12144/zgmfskin202103157

• 短篇论著 • 上一篇    下一篇

司库奇尤单抗治疗儿童银屑病六例疗效评价

谢辉1,牛美丽2,王新慧1,刘渠1,苗国英2   

  1. 1河北工程大学临床医学院，河北邯郸，056000；2河北工程大学附属医院，河北邯郸，056000
  • 出版日期:2021-03-15 发布日期:2021-03-03
  • 通讯作者: 苗国英，E-mail: guoyingmiao@163.com

Assessment of the efficacy of Secukinumab in the treatment of six cases of childhood psoriasis

XIE Hui1, NIU Meili2, WANG Xinhui1, LIU Qu1, MIAO Guoying2   

  1. 1 Clinical Medical Collefe of Hebei University of Engineering, Handan 056000, China; 
    2 Affiliated Hospital of Hebei  Engineering University, Handan 056000, China
  • Online:2021-03-15 Published:2021-03-03
  • Contact: MIAO Guoying, E-mail: guoyingmiao@163.com

PDF (PC)

290

摘要： 目的：评价司库奇尤单抗注射液治疗儿童银屑病的临床疗效及安全性。方法：收集2020年1月1日至2020年5月1日传统治疗方法不佳的儿童银屑病患者，在第0、1、2、3、4周进行皮下注射司库奇尤单抗150 mg，每周一次，共5次。记录患者PASI及BSA评分。结果：司库奇尤单抗共治疗6例儿童银屑病，治疗第4周时，6例患者均达到PASI 90，BSA显著降低，未出现不良反应。结论：司库奇尤单抗注射液治疗儿童银屑病安全有效。

关键词: 儿童银屑病, 司库奇尤单抗

Abstract: Objective: To evaluate the clinical efficacy and safety of Secukinumab in the treatment of childhood psoriasis. Methods: The children with psoriasis who failed to respond to conventional treatments were given subcutaneous secukinumab 150 mg at week 0,1,2,3 and 4. The psoriasis area severity index (PASI) and body surface area (BSA) were assessed. Results: At week 4 of the treatment, all the 6 patients achieved PASI 90, and BSA significantly decreased, with no adverse reaction. Conclusion: Secukinumab is effective and safe for childhood psoriasis.

Key words: psoriasis in children, Secukinumab